Information

Name

Csernansky, John, MD

Title

Lizzie Gilman Professor

Email

jgc@northwestern.edu

Office Phone

312-926-2323

Department

Chair, Department of Psychiatry and Behavioral Sciences; Chair, Stone Institute of Psychiatry, Northwestern Memorial Hospital

Office

446 E. Ontario, Suite 7-200 Chicago

Website

http://psychiatry.northwestern.edu/index.php/faculty-bios-/faculty-bios-/john-csernansky-md/
http://psychiatry.northwestern.edu/index.php/nu-schizophrenia-research-group/

Areas of Research

Brain Imaging, Neurobiology of Disease, Systems Neuroscience

NU Scholar Profile

http://www.scholars.northwestern.edu/expert.asp?u_id=458

Recent Publications on PubMed

http://www.ncbi.nlm.nih.gov/pubmed?term=Csernansky%2C%20John%5BFull%20Author%20Name%5D&cmd=DetailsSearch

Current Research

Current Research

Research Interests: My research interests include in vivo neuroimaging of neuropsychiatric disorders, especially schizophrenia and Alzheimer disease, clinical trials of cognition-enhancing drugs, and the development of animal models for neuropsychiatric disorders with greater validity. We use structural and functional magnetic resonance (MR) imaging to collect information about the location and magnitude of abnormalities of brain structure and function in patients with schizophrenia and Alzheimer’s disease. In schizophrenia, we have found evidence of a progressive loss of gray matter and hypo-activation in temporal and parietal regions of the cerebral cortex and in the subcortical structures that are related to these cortical regions. In Alzheimer’s disease, our findings suggest that measures of gray matter loss in medial temporal lobe structure can be used as biomarkers of early disease. The goal of my research program is to improve the validity of psychiatric diagnosis in patients with schizophrenia, Alzheimer’s disease, and related disorders using measures of brain structure and function. In addition, measures of brain structure and function should also be useful as markers of the impact of new drug and non-drug treatments on disease processes.